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Abstract
Antimicrobial resistance is a global public health concern,Introduction: 
but the problems are context specific, with each county or setting facing
differing challenges. In Africa, third-generation cephalosporin resistant
Enterobacterales (3GCR-E) are of particular concern, given the widespread
reliance on ceftriaxone for treatment of severe infection in this setting. In
Malawi, despite the rising prevalence of 3GCR-E, the health impact of these
infections has not been described. This study is designed to estimate
attributable mortality, morbidity and economic cost of 3GC-R bloodstream
infection (BSI) in a large, urban hospital.
This study will investigate the burden of antimicrobial resistanceMethods: 
by recruiting a a prospective longitudinal cohort of patients who have
bloodstream infection with 3GCR-E, at Queen Elizabeth Central Hospital,
Blantyre, Malawi. Patients whose blood culture is positive for either 3GC-S
or 3GC-R Enterobacterales will be enrolled and provide clinical and
healthcare economic data. Patients will be followed throughout their
hospital stay and to 6-months post discharge. Mortality, direct and indirect
costs and other health outcomes will be compared between patients with
3GC-R and comparable 3GC-sensitive BSI. Based on our observation that
some patients with clinical suspicion of sepsis and 3GC-R BSI are surviving
without an effective antibiotic, we review each patient prospectively and
classify what role the isolated bacteria is playing in the patient’s clinical
presentation. These classifications will then be incorporated into our
analysis.
The study protocol has been approved by theEthics and dissemination: 
Malawi College of Medicine Research Ethics Committee and by the
Liverpool School of Tropical Medicine Research Ethics committee. Written
informed consent will be obtained from study participants or their
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 informed consent will be obtained from study participants or their
parents/guardians. Results will be submitted to international peer-reviewed
journals, presented at international conferences and shared with
participating communities and collaborators.
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Introduction
Antimicrobial resistance in sub-Saharan Africa
Antimicrobial resistance (AMR) is a property of micro-organisms 
which have evolved to survive exposure to the antimicrobials 
previously successfully used to treat them. Drug-resistant infec-
tions (DRIs) occur when AMR bacteria cause infection and 
have become a global public health problem1. In high-income 
countries, DRIs frequently remain amenable to therapy, albeit 
with more expensive antibiotics, thus incurring increase in health-
care costs. The greatest burden of DRIs, however, is expected to 
occur in low and middle-income countries, where alternative 
antibiotics are frequently unavailable or prohibitively expen-
sive, and the morbidity and mortality from these infections is 
predicted to be high2.
Third-generation cephalosporin resistant Enterobacterales 
(3GCR-E), have been identified by the World Health Organi-
zation (WHO) as critical priority pathogens on which national 
AMR programmes should focus their surveillance and 
reporting2. These pathogens are of particular importance in sub-
Saharan African hospitals, where the third-generation cepha-
losporin, ceftriaxone, is frequently relied upon in the empirical 
treatment of sepsis3–5.
Median proportions of third-generation cephalosporin resist-
ance (3GC-R) amongst bloodstream Enterobacterales in sub- 
Saharan Africa (sSA) are high, approaching 15% in Escherichia 
coli and 50% in Klebsiella6. The most comprehensive pub-
lished information on AMR trends in sSA, comes from Malawi, 
where blood culture surveillance data from patients present-
ing to Queen Elizabeth Central Hospital (QECH), has shown a 
recent, rapid rise in 3GC-R amongst Enterobacterales7. Between 
2003 and 2016, ESBL resistance rose from 0·7% to 30·3% in 
E.coli and from 11·8% to 90·5% in Klebsiella, contemporaneous 
to the widespread roll-out of ceftriaxone in the hospital since 
20057.
Knowledge gaps
Despite the rising prevalence of 3GC-R amongst key patho-
gens and a reliance on ceftriaxone for management of infection, 
the health impact of 3GC-R BSI in sSA has not been described6. 
Findings from large-scale cohorts in high-income settings, sug-
gest that these infections are associated with adverse patient out-
comes, including high mortality, length of hospital stay and total 
healthcare costs8–11, but only one published study from sSA 
has investigated health burden from AMR, finding a significant 
impact of 3GC-R on mortality12. Malawi is one of the few coun-
tries in sSA with a long-term blood-culture service, but the 
Malawian dataset, though comprehensive in its AMR prevalence 
and incidence estimates, does not link drug-resistant infections 
to clinical metadata such as patient outcomes7.
Study approach
This study is designed to help address these knowledge gaps 
and aims to estimate the attributable mortality, morbidity and 
economic cost of 3GC-R BSI infection in Malawi by recruit-
ing a prospective longitudinal cohort of patients who have 
bloodstream infection (BSI) with Enterobacterales. The burden 
and presentation of clinical infectious disease in sSA may not 
be the same as in resource rich settings, therefore a key strength 
of this study is its prospective nature, which enables investiga-
tors to collect high quality data by reviewing every patient alive 
by the time their culture is positive and to determine the 
role the isolated pathogen is playing in the clinical presentation.
The methodological challenges involved in designing studies 
that aim to accurately estimate the burden of AMR on patients 
and health systems, have recently been debated13. This consor-
tium reflected upon the need to use the counterfactual approach to 
assessing burden of AMR, assuming that the likelihood of death 
would have been different if the pathogen had been susceptible. 
This counterfactual approach is the one taken by this study, in 
which attributable mortality and other health outcomes will be 
estimated by making comparisons between patients with 3GC-R 
and comparable 3GC-sensitive bloodstream infections, recruited 
in a prospective observational cohort.
Typically, a blood culture yielding a member of the fam-
ily Enterobacterales would be considered to be of high clinical 
significance and thus trigger antimicrobial therapy to be com-
menced or refined. It would be unusual to classify such an 
organism as a contaminant14. Consequently, Enterobacterales are 
routinely included in AMR surveillance studies without further 
consideration11. In the Malawian context, however, the limited 
availability of carbapenems and aminoglycosides means that 
patients whose blood culture is positive for 3GCR-E frequently 
remain untreated with an agent to which the isolate is sus-
ceptible. Despite this, patients often recover, posing the ques-
tion, what role is the bacterial isolate playing in the patient’s 
presentation?
If Enterobacterales are genuinely present in blood cultures as 
contaminants or cryptic organisms in significant numbers, it 
would have profound implications for burden of AMR studies. 
Before the disease burden attributable to resistant bloodstream 
infections can be estimated, the role a given blood culture iso-
late is playing in the clinical episode must be characterised. This 
protocol has therefore been designed to leverage the prospec-
tive nature of this study to propose a method for classifying 
the impact of each positive blood culture on a patient, and the 
subsequent incorporation of these classifications into our analysis 
of morbidity, mortality and cost. We further describe the clinical, 
laboratory, economic, data-management and ethical components 
of the study.
Methods
Study design
The study is a prospective longitudinal observational cohort 
of patients whose blood culture is positive for Gram-negative 
pathogens, excluding Salmonellae, regardless of sensitivity 
pattern. Patients whose blood culture isolate is sensitive to ceftri-
axone will be recruited following the same procedures as those 
whose blood culture isolate is resistant, so that mortality, mor-
bidity and economic comparisons can be made between the two 
groups. Detailed inclusion and exclusion criteria are shown in 
Table 1. Salmonellae will be excluded as 3GC-R in non-Typhoidal 
Salmonella remains sporadic and has not yet been reported 
in Salmonella Typhi in Malawi.
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Table 1. Study inclusion and exclusion criteria.
Inclusion criteria
Blood culture is positive for non-Salmonella Enterobacterales or Acinetobacter
Patient is an inpatient at QECH or can be contacted for admission or assessment
Exclusion criteria
Blood culture is positive for Salmonella enterica (any serovariant)
Patient is unable to provide informed consent and there is no representative to provide informed consent
Patient speaks neither English or Chichewa 
Study site
Malawi has a population of 17.5 million people and is 
classified as low income by the World Bank (2018 GDP of 
US$ 7.1 Billion, ranking 149th out of 205 economies)15. 
Blantyre is the second city of Malawi, with a population of 800,264 
and is located in Blantyre district, population 995,000 (2018 
census). The study will be being conducted at Queen Elizabeth 
Central Hospital (QECH), the largest government hospital in 
the country. QECH provides free healthcare to Blantyre and the 
surrounding districts, plus tertiary care to Malawi’s Southern 
region. It has 1,300 beds, frequently operating above capac-
ity. In July 2017, the Mercy James Centre (MJC) for Paediatric 
Surgery and Intensive care was opened as a separate 50-bedded 
building, operating as part of QECH. MJC receives approxi-
mately 1,600 admissions per year and houses the country’s only 
Paediatric Intensive Care Unit (PICU).
Blood culture service
A diagnostic blood-culture service, provided through the 
Malawi-Liverpool Wellcome Trust Clinical Research Programme 
(MLW) was established in 1998. MLW is affiliated with the 
Malawi College of Medicine and operates this service, 
7 days/week, providing free aerobic blood cultures and cer-
ebral spinal fluid (CSF) analysis to adult medical and paediatric 
patients. From March 2018, this service was extended to the 
Department of Obstetrics and Gynaecology, with a limited 
number of blood cultures offered per month.
Clinical blood culture protocols at QECH state that in adults, 
7–10mls of blood should be taken in patients presenting to 
the emergency department with a fever (axillary temperature 
> 37.5C) or clinical suspicion of sepsis, severe sepsis or sep-
tic shock. In children, 1–2 mls of blood is taken in patients with 
non-focal febrile illness and a negative malaria test or in chil-
dren with malaria whose fever persists despite treatment. A blood 
culture is also recommended in all premature or febrile neonates 
who are admitted to the neonatal unit. In a busy hospital with 
constrained resources and limited alternative diagnostics, 
blood cultures are often done on patients who do not fulfil these 
criteria, but at the discretion of the attending clinician. These 
patients will not be excluded from our analysis.
Blood is inoculated into a single aerobic bottle using the 
automated BacT/ALERT system (bioMerieux, France). Entero-
bacterales and Acinetobacter are identified to species level using 
Analytical Profile Index testing (API) (bioMerieux, France). 
Before March 2019, antimicrobial sensitivity testing (AST) was 
carried out as per British Society of Antimicrobial Chemother-
apy (BSAC) guidelines16, and from March 2019, as per European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines17. All blood culture isolates for patients recruited 
to the study will be regrown by a study laboratory technician 
and AST carried out as per EUCAST. The direct colony suspen-
sion method will be used to make a suspension of pure colony 
in 1ml 0.9% sterile saline solution, to the density of 
0.5 McFarland turbidity standard. The resulting suspension 
will be streaked evenly onto Muller-Hinton agar (MHA), aim-
ing for confluent bacteria growth. Antimicrobial discs will be 
applied and the resulting AST plates incubated at 35°C for 
18 (+/-2 hours). Zones of inhibition for each antimicrobial will 
be measured to the nearest millimeter and susceptibility catego-
ries interpreted according to EUCAST breakpoint tables18. The 
laboratory adheres to UK National External Quality Assessment 
Service (NEQAS)19.
The absolute number of blood cultures collected fluctuates 
on an annual basis, but has approached 15000 per year since 
2013. The most commonly isolated pathogens are non- 
typhoidal Salmonellae, Salmonella Typhi and Streptococcus 
pneumoniae (estimated minimum incidence ≥300/year) followed 
by the other Enterobacterales, in particular E.coli and 
Klebsiella spp. (50–299/year)7.
Participant selection and enrolment procedures
Daily reviews of the blood culture bench in the MLW microbiol-
ogy laboratory will be conducted on Monday to Friday, to identify 
consecutive blood cultures which are positive for pathogens of 
interest. Blood cultures which become positive over a weekend 
will be identified on a Monday morning. Once the blood cul-
ture result is final, patients will be identified in the hospital and 
enrolled following informed consent, aiming for recruitment 
as soon as possible after the final blood culture result is known. 
If a patient has been discharged by the time the final blood 
culture result is available, they will be contacted for review and 
potential recruitment if contact details are available. If a patient 
has died by the time the final result is available, their medical 
records will be collected for review.
At enrolment, a baseline questionnaire will be conducted, collect-
ing demographic and clinical information including admission 
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physiology, pre-hospital healthcare attendance, health-related 
quality of life (HRQoL) and a health-care utilisation survey. 
Questionnaires will be completed by a combination of patient 
interview, medical note review, and guardian interview if the 
patient is a child or is obtunded. In patients who have died by the 
time the blood culture is identified, the same questionnaires will 
be completed via medical note review, with data recorded as 
missing if it is not available. Vital signs will be performed by 
the study nurse at enrolment and patients assessed by a study 
clinician who will review the admission history and carry 
out clinical history and examination where indicated.
Sample collection
Blood samples will be collected from participants at 
enrolment and used to provide a set of baseline parameters that 
will aid in the clinical assessment of the participants illness. Blood 
will be tested for Full Blood Count (FBC) and creatinine and 
for CD4 count if HIV infected. Point of care tests will be car-
ried out on capillary blood for capillary lactate (Lactate Pro 2, 
Arkray, Japan) and quantitative C-Reactive Protein (CRP) (CRP 
single test kit , used with the NycoCard II Reader, Abbott, UK, 
1116078 and SBUK0028). HIV testing will be done as part of 
routine patient care, following Malawi national guidelines20. 
If a patient’s HIV status is unknown at the time of recruitment, 
they will be referred for HIV testing and counselling via stand-
ard QECH pathways. Urine will be collected at enrolment for 
screening dipstick and cultured if the dipstick is positive 
for leucocytes or nitrites. One stool sample will be taken at 
enrolment, or a rectal swab if it is not possible for a patient to 
provide stool. All other sample collection including urinary 
lipoarabinomannan (uLAM), and Sputum Xpert are done at the 
discretion of the clinical team providing routine care for the 
patient.
Follow up procedures
Patients will be followed up throughout their admission until 
discharge or death, allowing for measurement of in-hospital 
mortality. To allow for survival analysis and calculation of 
28-day and 6-month mortality, patients or their families will 
be telephoned at 28-days, three and six months post discharge. 
At follow-up, patients will be questioned to establish details of 
any antimicrobials received or healthcare facility usage since 
the last phone contact. If a patient dies, family members are 
asked the date of death.
Classification of Gram-negative blood culture
A preliminary set of classifications will be developed to 
describe the impact of each positive blood culture on each par-
ticipant, following the anecdotal observation that patients were 
surviving 3GC-R BSI episodes without receiving an antibiotic 
to which the organism is sensitive. These categories will initially 
be developed by the study PI (a specialist trainee in infectious 
diseases), and will be used to broadly classify each BSI episode 
into the following categories: definite Gram-negative sepsis, 
probable Gram-negative sepsis, transient or occult bacteraemia, 
or contaminated blood culture.
An expert panel, consisting of locally experienced physicians, 
adult and paediatric infectious disease specialists and a consultant 
microbiologist will then be assembled to pilot and finalise the 
classifications. This group will be presented with clinical vignettes 
for six patients and asked to anonymously classify each patient 
into the set of preliminary categories. An example of these 
vignettes, as they will be presented to the panel, are shown in 
Table 2. Any discrepancies in classifications will be dis-
cussed between the group and a final set of classifications and 
definitions decided. These classifications are shown in Table 3.
On completion of recruitment, the first 50 study participants 
will be presented to the expert panel and classified into definite/ 
probable or possible Gram-negative sepsis, transient or occult 
bacteraemia, or definite/probably contaminant (Table 3). For 
neonatal patients, a consultant neonatologist will be included. The 
panel will first be asked to anonymously categorise the partici-
pants and individual responses will be recorded. Any discrepan-
cies will be discussed and resolved by consensus. Following 
review and classification of the first 50 participants, the panel will 
re-assess the classification process to decide if sufficient clinical 
and laboratory data are available to confidently classify patients 
in this manner. At a minimum, patients will be objectively defined 
on the basis of: 
1.    Having a severe inflammatory response syndrome (SIRS) 
or not;
2.    Their treatment response (got better with or without 
active antibiotics or died with or without active 
antibiotics).
In addition, the panel will be asked for consensus on likely 
focus of clinical infection in patients who are considered to have 
a definite/probable or possible Gram-negative sepsis (Table 4). 
The panel will be asked to classify into likely rather than definite 
focus, because of a desire not to overclassify non-focal sepsis 
in a setting were lack of diagnostic resources frequently limit 
the ability to definitively confirm focus of infection.
Data analysis plan for primary outcomes
The effect of 3GC-R on mortality and discharge alive will be 
estimated using a logistic regression model for 28-day mortal-
ity and a Cox proportional hazards model for time to death. In 
the first instance, these models will be fitted to mortality data 
from the complete cohort. Uncertainty in true bloodstream infec-
tion status will then be explored using a latent variable approach 
and a Bayesian paradigm. Taken together with BSI incidence esti-
mates from Blantyre7, this will allow estimation of mortality from 
BSI in the Blantyre, assuming that cases admitted to QECH are 
representative of the general population. We will use hospital 
length of stay as a proxy outcome measure for morbidity8. 
To estimate length of hospital stay associated with 3GC-R, we 
will use multistate modelling, with time from hospital admission 
as the time scale21. Statistical analyses will be conducted using R 
(R Foundation for Statistical Computing, Vienna, Austria).
Health economic components
The health economic data collection will allow for three types 
of comparisons between patients with 3GC-R and 3GC-S BSI: 
healthcare provider costs, costs incurred by patients and their 
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Table 2. Participant vignettes: three example participants discussed at the consensus meeting, shown with final 
decisions on patient classification.
Participant-1 
 
E.coli 
 
S: ceftriaxone, chloramphenicol, 
gentamicin, ciprofloxacin, 
meropenem 
 
R: ampicillin, cotrimoxazole 
 
Classification: 
Definite Gram-negative sepsis
26 year old female 
 
HIV negative, normally fit and well. 
2 weeks postpartum. Caesarian section done at Queen Elizabeth Central Hospital. 
Unwell for 10 days post-operatively: abdominal pain, and fevers. 
 
 
Admission: Temperature 40.0°C. SIRS = Yes 
 
Recruitment Day 7: Temperature 37.0°C. SIRS= Yes 
Wound clean. No urinary catheters. Urine dipstick negative. 
 
Antibiotics: 9 days ceftriaxone, 5 days ciprofloxacin 
 
Bloods Day 7: WCC 8.3 x109 L-1, CRP 91 mg/L, Lactate 2.6, 
 
Outcome: Discharged alive
Participant-2 
 
E.coli 
 
S: ceftriaxone, chloramphenicol, 
gentamicin, ciprofloxacin, 
meropenem 
 
R: ampicillin, cotrimoxazole 
 
Classification: 
Definite Gram-negative sepsis
72 year old male 
 
HIV positive, on ART 10 years. Benign prostatic hyperplasia. Unwell for 3–4 weeks: 
confusion, cough, weight loss, lethargy. 
 
Pre-hospital: Co-amoxiclav and azithromycin within 1 month of admission. Week 2 TB 
Treatment 
 
Admission: Temperature 35.7°C, GCS 10. SIRS = Yes 
 
Recruitment Day 5: Temperature 37.5°C. SIRS = No 
 
Bloods Day 5: CD4 158 μL-1, WCC 26.0 x109 L-1,CRP >120mg L-1, lactate 3.4mmol L-1, 
creatinine 862mmol L-1 
 
Antibiotics: Ceftriaxone 24 hours 
 
Outcome: Died in hospital
Participant 3 
 
E.coli 
 
S: chloramphenicol, gentamicin, 
amikacin, meropenem,  
co-amoxiclav 
 
R: ceftriaxone, ampicillin, 
cotrimoxazole, ciprofloxacin 
 
 
 
 
Classification: 
Possible Gram-negative 
sepsis
32 year old woman, 
 
HIV positive, ART 2 years. Mechanical fall into drain, pain in hip and hx of fevers 
24 hours later. Associated headache and diarrhoea. Presented to Emergency 
Department after 5 days, had blood culture and outpatient follow-up arranged. No 
vital signs available on admission. Discharged on no antibiotics. 
 
 
 
 
 
Bloods Day 6: WCC 6.3 x109 L-1, creatinine 39mmol L-1,CD4 847μL-1, lactate 2.6mmol L-1, 
CRP 36mg L -1, urine dip negative 
 
Repeat blood culture on Day 6 = negative, no antibiotics in between 
 
Antibiotics: one dose of gentamicin on day 6, then discharged on nothing. 
 
Outcome: Discharged alive
Abbreviations: SIRS, systemic inflammatory response syndrome; ART, antiretroviral therapy; WCC, white cell count; CRP, C-reactive protein
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Table 3. Classification scheme for Gram-negative blood cultures.
Category Definition
Definite Gram-negative 
sepsis consequent upon 
cultured isolate
The blood culture isolate is contributing to the patient’s clinical state and treatment was 
considered to be required.
Probable Gram-negative 
sepsis consequent upon 
cultured isolate
The blood culture isolate is probably contributing to the patient’s clinical state, but there is 
insufficient evidence to confirm or refute this. Treatment was considered to be required
Possible Gram-negative 
sepsis consequent upon 
cultured isolate
The blood culture isolate may be contributing to the patient’s clinical condition, but the patient 
improved without antibiotics predicted to be active based on antimicrobial susceptibility 
testing, and it is not possible to confirm or refute definite/probably Gram-negative (GN) sepsis. 
 
i.e. Treatment was considered to be required but the patient improved without antibiotics likely 
to be active against the isolate.
Occult or transient 
bacteraemia
The blood culture isolate may have contributed to the patient’s clinical condition, but by the 
time they are assessed with the culture, they have improved. 
 
Unlike the definition for ‘possible GN sepsis’, treatment was not considered to be required, but 
instead a repeat blood culture was desirable.
Definite contaminant The isolate has never contributed to patient’s condition and was very likely not present in the 
bloodstream
Probable contaminant The isolate probably never contributed to patient’s condition and was probably not present in 
the bloodstream/or there is insufficient evidence to say for sure.
Table 4. Clinically suspected focus of infection.
Focus
Non-focal 
Central-line associated 
Clear focus of infection 
       •   Urinary tract infection 
       •   CNS 
       •   Skin and soft tissue 
       •   Gastrointestinal (hepatobiliary) 
       •   Gastrointestinal (non hepatobiliary) 
       •   Cardiovascular system 
       •   Respiratory tract infection (other than VAP) 
       •   Reproductive tract infection 
       •   Surgical site infection 
       •   Bone and joint 
       •   Post-operative, non-focal 
       •   VAP 
Unknown 
Other
Abbreviations: CNS, central nervous system; VAP, 
ventilator associated pneumonia
families as a result of hospitalisation, and health-related quality 
of life (HRQoL). Primary costing studies and data capture tools 
described below have been developed and validated for adult 
inpatients only22, therefore children under 18 are excluded 
from this component of the study.
Healthcare provider costs. Upon discharge or death, informa-
tion from the patient’s medical record will be extracted by a 
study clinician, to establish the medications and dosages given, 
duration of hospital admission, types and numbers of investiga-
tions and procedures performed and the participant’s outcome. 
Costs of these healthcare resources will be derived from a pre-
vious primary costing study undertaken at QECH22. The inter-
national market price will be used to estimate costs for all 
medication given23.
Direct non-medical and indirect costs. Questionnaires will 
be administered to patients and their guardians as soon as 
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possible after recruitment. All questionnaires are provided as 
extended data24. Data collected will include cost of transportation, 
food, drinks, toiletries, clothing and other items bought during 
the hospital admission. For indirect costs, any time off work 
taken by participants or their guardians is recorded together with 
self-reported income. The development and language translations 
of these questionnaires followed previous procedures22,25.
Health-related quality of life. The Chichewa version of the 
EuroQoL EQ-5D-3L will be used to assess HRQoL of partici-
pants at recruitment and discharge from hospital as well as at 
28-day follow-up26. The EQ-5D has a descriptive component 
asking participants to rate their health status across a number of 
domains and a visual analogue scale (VAS) similar to a 
thermometer, and ranges from 100 (best imaginable health state) 
to 0 (worst imaginable health state). EQ-5D utility scores will 
be derived from responses to the descriptive components using 
the Zimbabwean EQ-5D tariff set27.
Mean differences in total direct health provider cost, total direct 
non-medical and indirect cost and HRQoL outcomes between 
participants with 3GC-R and 3GC-S bloodstream infections will 
be estimated. Non-parametric bootstrap methods will be used to 
account for possible skewness in distribution of economic data. 
Multivariable analysis will be undertaken to explore the inde-
pendent effects 3GC-R on these economic costs and HRQoL 
outcomes. For HRQoL outcomes, EQ-5D utility and VAS scores 
will also be compared between participants at recruitment, 
discharge and follow-up where data are available.
Data capture and storage
Data will be collected using Open Data Kit software (ODK, 
1.4.10) and TeleForm Data Capture Software (10.7). Completed 
ODK forms are pushed daily to a dedicated secure SQL database. 
Teleform paper forms will be checked, scanned and validated 
by the MLW data team, in discussion with the clinical team if 
required and validated TeleForm data pushed to the SQL data-
base. Completed paper TeleForm records will be stored securely 
in the MLW data department. All data on the study database 
will be stored securely with access restricted to the study PI 
and the database administrators in the MLW data department. 
Results of laboratory investigations in the MLW laboratory 
will be stored in the MLW PreLink laboratory information man-
agement system (LIMS), anonymised and linked only to the 
participant unique study ID number.
Sample size considerations
The study is powered to detect a difference in 28-day mortality 
rates between participants with 3GC-R and 3GC-S bloodstream 
infection. There are no studies from sSA powered to detect 
mortality from ESBL BSI, on which to guide our sample size 
estimates, but a large multi-centre European study found that 
mortality was 14% higher in patients who had an ESBL positive 
BSI versus those who had ESBL negative BSI28. Based on 
this, we aim to recruit 250 patients to the cohort, which would 
provide 80% power to detect a difference in 28-day mortality 
rates of 10% vs. 24.1%. If this recruitment target is not achieved, 
a more modest 200 patients would still provide 80% power 
to detect mortality of 10% vs 25.8%. These calculations assume 
a 50:50 split in 3GC-R and 3GC-S infections, based on 2016 
figures7. An imbalance in this split will have minimal impact 
on the statistical power of the study. We are aiming to recruit 
250 patients who have definite, probable or possible Gram- 
negative sepsis, therefore have inflated the overall sample size to 
350 participants given that some patients will be censored from 
the study following expert case review.
Ethics
Ethical approval for the study was granted by the Malawi Col-
lege of Medicine Research Ethics Committee (COMREC), 
protocol number P.10/17/2299 and by the Liverpool School of 
Tropical Medicine Research Ethics committee, protocol number 
17-063. LSTM acted as the study sponsor. Written informed 
consent is obtained from study participants, the participant’s 
parent/guardian if they are a child aged 18 years, or from a 
guardian if the patient lacks capacity to consent.
Dissemination
Results from this study will be presented internally within 
the College of Medicine and QECH, Malawi College of Medi-
cine Research Ethics Committee and disseminated to the Ministry 
of Health, Malawi. Manuscripts will subsequently be prepared 
for publication in peer-reviewed journals, which will be made 
freely available via open-access publication.
Study status
Recruitment to the study is currently ongoing and is expected 
to be completed in March 2020.
Discussion
This study is designed to investigate the attributable morbidity, 
mortality and economic cost of third-generation cephalosporin 
resistant bloodstream infections in Malawi, a country which 
has the largest bacteraemia and AMR surveillance dataset 
from sSA, but in which the health burden of AMR infections is 
currently unknown. We aim to address this knowledge gap 
by assessing the healthcare burden of resistance to one of the 
most commonly used and frequently last-line antibiotics in 
hospitalised inpatients in Malawi.
Our approach of prospective recruitment and detailed charac-
terisation of all BSI episodes will generate reliable data on the 
impact of bloodstream infection on patients, and in turn, the bur-
den of 3GC-R infection. In line with recently published guidance 
on quality reporting of AMR data29, we will be able to provide 
a clear account of microbiological sampling criterial, sam-
pling frame and laboratory methods, as well as clinical metadata 
including empiric antibiotic regimens, HIV status and healthcare 
attendance.
This study is limited to one hospital but it is hoped that these 
data will be used to generate accurate burden estimates for 
Malawi, and that the methods will be replicated by future 
investigators wishing to generate robust data on the impact of 
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drug-resistant infections. By estimating attributable mortality, 
morbidity and economic cost in a prospective cohort, we will gen-
erate high quality data that will be amongst the first of their kind 
from sSA and that will consequently be able to inform global 
burden of disease estimates
Data availability
Underlying data
No data are associated with this article
Extended data
Zenodo: Case report forms (CRFs) used for the publication: 
Estimating the burden of antimicrobial resistance in Malawi: 
protocol for a prospective observational study of the morbidity, 
mortality and economic cost of third-generation cephalosporin 
resistant bloodstream infection. http://doi.org/10.5281/zenodo. 
363446624
This project contains the following extended data:
- CRFs_Wellcome.pdf (Study questionnaires)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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